Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04702880
Title A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bristol-Myers Squibb

lung small cell carcinoma


BMS-986012 + Carboplatin + Etoposide + Nivolumab

Carboplatin + Etoposide + Nivolumab

Age Groups: adult | senior
Covered Countries USA | ITA | ESP | CAN | BEL

No variant requirements are available.